Your browser is no longer supported. Please, upgrade your browser.
ARQT Arcutis Biotherapeutics, Inc. monthly Stock Chart
Arcutis Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-3.45 Insider Own2.50% Shs Outstand37.75M Perf Week21.27%
Market Cap1.05B Forward P/E- EPS next Y-4.01 Insider Trans- Shs Float20.56M Perf Month28.86%
Income-114.20M PEG- EPS next Q-0.85 Inst Own79.80% Short Float5.51% Perf Quarter5.45%
Sales- P/S- EPS this Y-118.10% Inst Trans3.13% Short Ratio4.93 Perf Half Y-23.68%
Book/sh4.58 P/B5.66 EPS next Y-2.60% ROA-57.70% Target Price- Perf Year-
Cash/sh4.70 P/C5.52 EPS next 5Y9.80% ROE-81.70% 52W Range17.10 - 40.88 Perf YTD18.99%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.55% Beta-
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low51.70% ATR1.39
Employees29 Current Ratio9.20 Sales Q/Q- Oper. Margin- RSI (14)66.28 Volatility6.13% 6.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-156.00% Profit Margin- Rel Volume0.21 Prev Close25.62
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume229.77K Price25.94
Recom1.80 SMA2023.81% SMA5012.27% SMA200-2.50% Volume48,571 Change1.25%
Nov-09-20Upgrade Goldman Neutral → Buy $34 → $36
Oct-08-20Initiated Truist Buy $38
Feb-25-20Initiated Guggenheim Buy $36
Feb-25-20Initiated Goldman Neutral $30
Feb-25-20Initiated Cowen Outperform $55
Feb-25-20Initiated Cantor Fitzgerald Overweight $50
Nov-27-20 11:55AM  
Nov-23-20 07:30AM  
Nov-11-20 04:05PM  
Nov-05-20 04:05PM  
Nov-04-20 04:05PM  
Nov-02-20 09:00AM  
Oct-29-20 09:07PM  
Oct-26-20 09:00AM  
Oct-08-20 10:00AM  
Oct-06-20 04:05PM  
Oct-02-20 12:40PM  
Oct-01-20 10:47PM  
Sep-29-20 04:51PM  
Sep-16-20 09:00AM  
Sep-15-20 09:00AM  
Sep-08-20 09:00AM  
Aug-11-20 04:02PM  
Aug-10-20 09:00AM  
Aug-04-20 09:00AM  
Aug-03-20 09:00AM  
Jul-31-20 09:00AM  
Jul-27-20 09:00AM  
Jul-20-20 09:00AM  
Jul-15-20 05:07PM  
Jul-13-20 09:00AM  
Jun-22-20 11:47AM  
Jun-10-20 04:05PM  
Jun-01-20 09:00AM  
May-27-20 09:00AM  
May-12-20 04:05PM  
Apr-27-20 08:30AM  
Apr-21-20 09:00AM  
Mar-23-20 08:30AM  
Mar-16-20 08:37AM  
Mar-05-20 08:30AM  
Mar-03-20 08:30AM  
Feb-19-20 08:30AM  
Feb-14-20 08:00PM  
Feb-13-20 08:30AM  
Feb-04-20 04:05PM  
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Welgus Howard G.DirectorNov 12Option Exercise0.581,222709179,844Nov 13 11:57 AM
Welgus Howard G.DirectorNov 02Option Exercise1.682,2003,696180,822Nov 04 04:33 PM
Welgus Howard G.DirectorNov 02Sale18.272,20040,186178,622Nov 04 04:33 PM
Lock Kenneth A.Chief Commercial OfficerOct 26Option Exercise6.522,66817,39521,863Oct 27 02:03 PM
Lock Kenneth A.Chief Commercial OfficerOct 22Option Exercise6.522,69517,57119,195Oct 23 01:27 PM
Lock Kenneth A.Chief Commercial OfficerOct 15Option Exercise6.527,50048,90016,500Oct 16 02:06 PM
Welgus Howard G.DirectorOct 15Option Exercise0.581,222709178,622Oct 16 02:06 PM
ORBIMED ADVISORS LLCDirectorOct 02Buy25.00496,00012,400,0004,267,564Oct 06 05:27 PM
SILVERSTEIN JONATHANDirectorOct 02Buy25.00496,00012,400,0004,267,564Oct 06 05:23 PM
Welgus Howard G.DirectorOct 01Option Exercise1.682,2003,696179,210Oct 05 09:13 PM
Welgus Howard G.DirectorOct 01Sale27.652,20060,829177,400Oct 05 09:13 PM
Smither John WChief Financial OfficerSep 29Option Exercise1.6850084024,375Oct 01 09:00 PM
Watanabe Todd FranklinPresident and CEOSep 29Option Exercise1.683,0005,042569,928Oct 01 09:02 PM
Watanabe Todd FranklinPresident and CEOSep 29Sale30.003,00090,000566,928Oct 01 09:02 PM
Smither John WChief Financial OfficerSep 29Sale30.001,25037,50098,715Oct 01 09:00 PM
Smither John WChief Financial OfficerSep 29Sale30.0050015,00023,875Oct 01 09:00 PM
OSBORNE DAVID WChief Technical OfficerSep 29Sale30.0015,000450,000264,279Oct 01 09:01 PM
Welgus Howard G.DirectorSep 15Option Exercise0.581,222709177,400Sep 16 05:57 PM
Welgus Howard G.DirectorSep 01Option Exercise1.682,2003,696178,378Sep 02 11:48 AM
Welgus Howard G.DirectorSep 01Sale24.382,20053,643176,178Sep 02 11:48 AM
Welgus Howard G.DirectorAug 20Option Exercise1.685,0008,400176,178Aug 21 02:19 PM
Welgus Howard G.DirectorAug 18Option Exercise1.685,0768,528171,178Aug 19 05:48 PM
Welgus Howard G.DirectorAug 14Option Exercise0.586,1103,545166,102Aug 18 04:12 PM
Welgus Howard G.DirectorAug 03Option Exercise1.682,8004,704162,725Aug 05 05:11 PM
Welgus Howard G.DirectorAug 03Sale25.632,80071,764159,992Aug 05 05:11 PM
Smither John WChief Financial OfficerJun 11Option Exercise1.6814,87524,999123,840Jun 15 03:15 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.